CASP9 and neoplasm: In breast cancer models, PEP-010 targets the interaction between caspase-9 and protein phosphatase 2A (PP2A), with preclinical in vivo studies demonstrating significant tumor regression, underscoring its therapeutic potential for aggressive cancers [23,24].